CVKD vs TXT · $20.2M cap vs P/E 19, rev $7.52B
Cadrenal Therapeutics, Inc. Common Stock (CVKD) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a biotechnology company listed on US.
Textron Inc (TXT) is a aerospace & defense company listed on US.
CVKD does not have a complete income-statement cache yet.
Latest reported TXT revenue for 2026-07-04 was $7.52B. Net income was $468.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
CVKD currently screens at market cap $20.2M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the CVKD and TXT stock pages for the full models.
Not investment advice.